David Scott Moore

CIK: 0002088466

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CRVS

Corvus Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

CRVS
Corvus Pharmaceuticals, Inc.
Jun 11, 2026
Purchase(P)
Direct
21.7K shares at avg. $11.53$250K
CRVS
Corvus Pharmaceuticals, Inc.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
15K shares-
CRVS
Corvus Pharmaceuticals, Inc.
Oct 2, 2025
Award(A)
Stock Option (Right to Buy)
Direct
30K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	CRVS Corvus Pharmaceuticals, Inc.	Purchase(P)	21,700	$11.53	$250,236	Direct
Jun 11, 2026	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	15,000	-	-	Direct
Oct 2, 2025	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	30,000	-	-	Direct

1-3 of 3 transactions

About Moore David Scott

Moore David Scott (SEC CIK 0002088466) files insider reports with the SEC as Director of Corvus Pharmaceuticals, Inc. (CRVS).

Signal8 holds 3 ownership filings by Moore David Scott (1 Form 3, 2 Form 4), filed between Oct 6, 2025 and Jun 15, 2026. Those filings report 3 transactions, from Oct 2, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Moore David Scott's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Moore David Scott

Jun 11, 2026: Open-market purchase of CRVS shares (Form 4, code P).
Jun 11, 2026: Grant or award of CRVS derivative securities (Form 4, code A).
Oct 2, 2025: Grant or award of CRVS derivative securities (Form 4, code A).

Other insiders filing for Corvus Pharmaceuticals, Inc. (CRVS)

CLARK IAN T, Director
Grais Linda, Director
Thompson Peter A., Director
van den Broek Richard, Director
MILLER RICHARD A MD, President and CEO
Chan Andrew C., Director

How to read Form 4 transaction codes